Regulatory feed
Published med-spa & injectable compliance alerts · monitoring, not legal advice
Free
Enter your email to unlock “What to do” on every alert — and get the weekly Brief. No charge.
Want it filtered to YOUR states + real-time alerts? Become a member →
- MONITORFEDGLP-1 Compounding2026-06-26
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
FDA extends comment period on GLP-1 compounding decisions.
What to do — free with your email (above).Federal Registerprimary source ↗ - CRITICALFEDMarketing & Advertising2026-06-12
FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
FTC targets deceptive health claims affecting aesthetic practices.
What to do — free with your email (above).FTC Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-06-11
FDA shortage: Liraglutide Injection (Injection) — Current
FDA drug shortage enables lawful GLP-1 compounding.
What to do — free with your email (above).FDA Drug Shortagesprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-06-04
FDA shortage: Semaglutide Tablet (Tablet) — To Be Discontinued
Semaglutide discontinuation affects GLP-1 compounding.
What to do — free with your email (above).FDA Drug Shortagesprimary source ↗ - CRITICALFEDGLP-1 Compounding2026-05-27
FDA recall (Class II): Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, …
FDA recalls contaminated Liraglutide Injection; check your inventory!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 Compounding2026-05-26
FDA / Federal Register Notice: Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
FDA seeks comments on human drug compounding regulations.
What to do — free with your email (above).Federal Registerprimary source ↗ - MONITORMAScope of Practice2026-05-26
MA H5455: Regulating the operation of medical spas
New regulations on med spas in Massachusetts could change operations.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORFEDGLP-1 Compounding2026-05-01
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
FDA evaluates bulk drug substances; GLP-1 agents may be impacted.
What to do — free with your email (above).Federal Registerprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-04-30
FDA / Federal Register Notice: Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
FDA ensures continued access to OZEMPIC for aesthetic practices.
What to do — free with your email (above).Federal Registerprimary source ↗ - MONITORCOMulti-topic2026-04-23
CO SB130: Medical Spas Deceptive Trade Practices
No immediate changes for Colorado med spas under SB130.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-04-22
FDA recall (Class II): Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Bea…
FDA recalls semaglutide compound over sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFLMulti-topic2026-03-13
FL S1728: Licensure of Medical Spas
Proposed licensure for medical spas would enhance oversight and compliance.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFLScope of Practice2026-03-13
FL H1429: Licensure of Medical Spas
New regulations for med spas on licensure and compliance.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-03-11
FDA recall (Class II): Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 843…
Important recall on compounded Semaglutide products affecting med spas.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2026-03-11
FDA recall (Class II): Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, …
FDA recalls Tirzepatide Inj over sterility concerns; check your stock!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-03-11
FDA recall (Class II): Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC …
FDA recalls Tirzepatide injection over sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2026-03-11
FDA recall (Class II): Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 843…
FDA recalls specific compounded GLP-1 products due to quality issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-03-11
FDA recall (Class II): Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, …
FDA recalls compounded GLP-1 product over sterility concerns.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2026-03-11
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061,…
FDA recalls Semaglutide for sterility issues—act now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALINNATIONALMulti-topic2026-03-05
IN SB0282: Compounding drugs; registration of medical spas.
New regulations for Indiana med spas take effect in 2027.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONINMulti-topic2026-03-04
IN HB1358: Indiana department of health.
Bill focuses on public health rather than aesthetic practices.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDGLP-1 Compounding2026-02-23
FDA / Federal Register Notice: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
New FDA notice may impact GLP-1 compounding practices at med spas.
What to do — free with your email (above).Federal Registerprimary source ↗ - MONITORAZScope of Practice2026-02-10
AZ HB4047: Medical spas; licensure; regulation
New licensure requirements for med spas in Arizona.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORMSMulti-topic2026-02-03
MS HB59: Nurses; allow nurse practitioners and RNs to administer vitamins through IV therapy in a clinical setting.
Bill allowing nurses to administer vitamin IV therapy has died.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORMSGLP-1 Compounding2026-02-03
MS SB2544: Mississippi Active Pharmaceutical Ingredient Quality Assurance Act; enact to impose certain provisions for compounding.
New regulations could impact drug compounding for med spas.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDAesthetic Devices2026-01-28
FDA device recall (Class II): Brand Name: LEASEIR Product Name: LEASEIR MHR XCELL Model/Catalog Number: MHR 110-b Software Version: 1.5.0.0 Product D…
Leaseir MHR Xcell laser recalled for safety issues.
What to do — free with your email (above).FDA Device Recallprimary source ↗ - MONITORMAMulti-topic2026-01-27
MA H5087: Regulating the operation of medical spas
New regulations for med spas could redefine injector practices.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORIAScope of Practice2026-01-20
IA HSB591: A bill for an act establishing the medical spa oversight Act, and making penalties applicable.
New regulation may change operations for Iowa med spas.
What to do — free with your email (above).LegiScanprimary source ↗ - CRITICALFEDGLP-1 Compounding2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 B…
FDA recalls Wegovy due to safety concerns; med spas must act.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
FDA recalls Wegovy; med spas must check supplies!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - MONITORPAScope of Practice2025-12-16
PA HB1881: Further providing for pharmacy technician and pharmacy technician trainee registration, qualifications and supervision; providing for administration of injectable medications, biologicals and immunizations, for clinical laboratory certificate and for report on pharmacy-administered vaccines; and making a repeal.
PA bill may expand pharmacy technicians' role in injectables.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-24
FDA / Federal Register Notice: Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
FDA seeks comments on human drug compounding practices.
What to do — free with your email (above).Federal Registerprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jef…
FDA recalls GLP-1 product; take immediate action.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Je…
FDA recalls Semaglutide injection over sterility issues; take action!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 J…
FDA recalls Semaglutide injection due to sterility concerns.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jef…
Urgent: FDA recalls compounded semaglutide injection.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 J…
FDA recalls Semaglutide injection due to sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeff…
FDA recalls GLP-1 injection over sterility concerns.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-11-05
FDA recall (Class II): Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeff…
Urgent FDA recall of Tirzepatide Injection impacts med spas.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - MONITORPAScope of Practice2025-10-17
PA SB1055: Further providing for pharmacy technician and pharmacy technician trainee registration, qualifications and supervision; providing for administration of injectable medications, biologicals and immunizations, for clinical laboratory certificate and for report on pharmacy-administered vaccines; and making a repeal.
PA's SB1055 could change injectable practice for pharmacy techs.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-10-15
FDA recall (Class II): Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 20…
Important FDA recall on GLP-1 compounded product—act now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-10-15
FDA recall (Class II): Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton…
FDA recalls GLP-1 product over sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-10-15
FDA recall (Class II): Semaglutide for Injection, a) 20 mg b) 20 mg/mL, 10 mL Multi-Dose Vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca R…
FDA recalls semaglutide over sterility issues; check your stock!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy
Med spas must act on the GLP-1 product recall now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
FDA recalls compounded GLP-1 product for being subpotent.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy
Urgent: GLP-1 injection recall for med spas sourcing compounded products.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2…
Important recall of GLP-1 compounded product—act now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
Important recall for GLP-1 products; take immediate action.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
FDA recalls compounded GLP-1 product due to processing controls issue.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2…
FDA recalls compounded GLP-1 product due to safety concerns.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2…
FDA recalls a GLP-1 product; check your supply immediately.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile…
FDA recalls compounded GLP-1 product; take immediate action!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) s…
Stay informed: GLP-1 injectable recall may affect your practice.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
Ongoing recall of compounded GLP-1 product: take action now.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
Alert: GLP-1 product recall due to processing issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
Important recall for compounded GLP-1 products impacts med spas.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
FDA recalls compounded GLP-1 product; check your stock now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile,…
FDA recalls compounded GLP-1 product over safety issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-08-13
FDA recall (Class II): Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2…
Important FDA recall for compounded GLP-1 product impacts med spas.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-07-30
FDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2026
New FDA fees for outsourcing facilities impact compounding.
What to do — free with your email (above).Federal Registerprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Tirzepatide/Cyanocobalamin Injectable, 15mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, S…
Recall alert: Check your GLP-1 injectable supplies now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Tirzepatide Injections, 10mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
FDA recalls Tirzepatide due to sterility concerns - take action now!
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Tirzepatide/Cyanocobalamin Injectable, 30mg/1mg/mL (15mg/0.5mg/0.5mL), pre-filled syringe, Thrive Health Solutions, 88 …
FDA recalls GLP-1 product due to sterility concerns.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Tirzepatide Injections, 20mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
FDA recalls Tirzepatide for sterility issues; take action now.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
FDA recalls compounded GLP-1 product over sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
FDA recalls Tirzepatide injections; action needed now.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80…
FDA recalls GLP-1 product over sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-07-02
FDA recall (Class II): Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Su…
FDA recalls compounded GLP-1 product for sterility issues.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALRINATIONALScope of Practice2025-06-30
RI H5351: Mandates cosmetic medical procedures be performed by a physician, PA, APRN, or delegated to a qualified non-physician, non-PA or non-APRN under the supervision of a physician, physician assistant, or advanced practice registered nurse.
New RI law tightens regulations for med spas and injectors.
What to do — free with your email (above).LegiScanprimary source ↗ - CRITICALRIScope of Practice2025-06-30
RI S0976: Mandates cosmetic medical procedures be performed by a physician, PA, APRN, or delegated to a qualified non-physician, non-PA or non-APRN under the supervision of a physician, physician assistant, or advanced practice registered nurse.
New supervision rules impact med spa procedures in Rhode Island.
What to do — free with your email (above).LegiScanprimary source ↗ - CRITICALFEDGLP-1 Compounding2025-05-07
FDA recall (Class II): Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
Urgent recall of Wegovy due to temperature abuse risks.
What to do — free with your email (above).FDA Enforcementprimary source ↗ - CRITICALCOScope of Practice2025-04-07
CO HB1024: Medical-Aesthetic Services Delegation Disclosures
New disclosure requirements for delegated aesthetic services.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONMSGLP-1 Compounding2025-02-13
MS HB1430: Prescription drugs; prohibit licensing boards from prohibiting practitioners from prescribing for off-label use.
Potential changes in off-label prescribing regulations in Mississippi.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORMSScope of Practice2025-02-04
MS HB620: Nurses; allow nurse practitioners and RNs to administer vitamins through IV therapy in a clinical setting.
Proposed bill for nurse-administered IV vitamin therapy died.
What to do — free with your email (above).LegiScanprimary source ↗ - CRITICALILScope of Practice2025-01-07
IL HB4281: CERTIFIED MEDICAL ESTHETICIAN
Licensed estheticians may now provide more services independently.
What to do — free with your email (above).LegiScanprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-01-07
FDA / Federal Register Notice: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
New FDA guidance impacts sourcing for compounding in med spas.
What to do — free with your email (above).Federal Registerprimary source ↗ - CAUTIONFEDGLP-1 Compounding2025-01-07
FDA / Federal Register Notice: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
New FDA guidance impacts GLP-1 compounding practices.
What to do — free with your email (above).Federal Registerprimary source ↗ - CAUTIONCTMulti-topic2024-06-06
CT HB05236: An Act Concerning Recommendations By The Department Of Consumer Protection.
New CT bill leaves room for changes impacting med spas.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORRIScope of Practice2024-05-22
RI H8296: Provides that the performance of cosmetic medical services is the practice of medicine and surgery.
Key changes for medical spas on cosmetic services oversight.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORRIScope of Practice2024-03-22
RI S2870: Provides that the performance of cosmetic medical services is the practice of medicine and surgery.
Proposed bill could redefine cosmetic services under medical practices.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORRIMulti-topic2024-03-01
RI H7820: Provides that licensed health care facilities be prohibited from using a patients photograph for any office use.
New RI bill impacts patient photo usage in med spas.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORSCNeuromodulators2023-03-07
SC H4084: Dental administration of neuromodulators
SC bill proposed for dental administration of neuromodulators.
What to do — free with your email (above).LegiScanprimary source ↗ - MONITORNHMulti-topic2022-12-23
NH HB105: Relative to the registration of medical spas.
No new registration requirements for NH med spas after HB105 failed.
What to do — free with your email (above).LegiScanprimary source ↗ - CRITICALTNScope of Practice2021-05-18
TN HB0915: AN ACT to amend Tennessee Code Annotated, Section 62-4-109, relative to the practice of aesthetics.
Tennessee aestheticians can now perform microneedling with supervision.
What to do — free with your email (above).LegiScanprimary source ↗ - CRITICALTNNATIONALScope of Practice2021-05-18
TN SB1339: AN ACT to amend Tennessee Code Annotated, Section 62-4-109, relative to the practice of aesthetics.
Tennessee aestheticians can now perform microneedling with physician oversight.
What to do — free with your email (above).LegiScanprimary source ↗